Rate Limiting Steps of AAV Transduction and Implications for Human Gene Therapy

Authors: Sanlioglu S.; Monick M.M.; Luleci G.; Hunninghake G.W.; Engelhardt J.F.

Source: Current Gene Therapy, Volume 1, Number 2, July 2001 , pp. 137-147(11)

Publisher: Bentham Science Publishers

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Despite the fact that adeno-associated virus type 2 (AAV2) is an extremely attractive gene therapy vector, its application has been limited to certain tissues such as muscle and the brain. In an attempt to broaden the array of target organs for this vector, molecular studies on the mechanism(s) of AAV transduction have expanded over the past several years. These studies have led to the development of innovative strategies capable of overcoming intracellular barriers to AAV2 transduction. The basis of these technologic breakthroughs has stemmed from a better understanding of the molecular processes that control AAV entry and intracellular trafficking to the nucleus. This review will focus on the identification of molecular components important for recombinant AAV (rAAV) transduction while highlighting the techniques used to discover them and potential clinical application of research findings.

Keywords: AAV Transduction; Human Gene Therapy; Recombinant AAV (rAA V); Viral Binding; Heparan sulfate proteoglycan; Nuclear Transport; Viral Uncoating; Nuclear Gene Conversion

Language: English

Document Type: Review article

DOI: 10.2174/1566523013348788

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy